BEAM Stock Price Today (June 2026) — Beam Therapeutics Inc. Analysis & Key Metrics 2026-06-18
Beam Therapeutics Inc. (BEAM) is trading at $34.14, up 5.11% today (as of June 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $51.07 (49.6% upside).
- Volatility remains elevated (76.04% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (3.25% YoY) alongside significant competitive pressures.
BEAM Stock Analysis: Key Metrics & Valuation (June 2026)
Concise, actionable data for investors
Beam Therapeutics Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $2.00B
P/E Ratio
Forward P/E: -6.28
Revenue Growth
Year over Year
Analyst Target
+49.6% upside potential
Key Investor Questions About BEAM
What investors need to know before buying
Based on current market data, BEAM presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 66.06)
- Fundamentals say: Caution warranted (high leverage concerns)
BEAM's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BEAM investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $250.82M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, BEAM stock traded between $15.60 and $36.44—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 76.04% annualized volatility and β=1.76, the stock exhibits high sensitivity to market moves—making BEAM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts?
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On May 18, 2026, Beam Therapeutics Inc. (NASDAQ:BEAM) presented updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference. The firm detailed safety, durability, and reduced neutrophil elastase activity following treatment. […]
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD
Earlier in May 2026, Beam Therapeutics presented updated Phase 1/2 BEAM-302 data in alpha-1 antitrypsin deficiency, including detailed safety, durability and human neutrophil elastase findings, and confirmed plans to seek an accelerated approval path with an expanded pivotal cohort of about 50 additional patients starting in the second half of 2026. The data suggest BEAM-302’s one-time base-editing approach may address both liver and lung manifestations of AATD while preserving natural,...
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?
Are there significant gains ahead for one (or both) of these innovative biotechs?
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year. Sp
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock
Beam Therapeutics Inc (NASDAQ:BEAM) is one of the best gene therapy stocks to buy in 2026. The stock is up roughly 27% in the past six months and soared more than 60% in the past year. The Street expects BEAM stock to pop almost 70% in the next 12 months as therapy programs continue to […]
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus
Beam Therapeutics (NasdaqGS:BEAM) reported positive Phase 1/2 data for its BEAM-302 program at a major international conference. The gene editing therapy showed durable restoration of alpha-1 antitrypsin function, targeting both lung and liver manifestations of the disease. Beam plans to expand the BEAM-302 trial and work with the FDA on a potential accelerated approval pathway. For investors watching genetic medicine, this update puts Beam Therapeutics back in focus. The stock last closed...
Frequently Asked Questions
Common investor questions about Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) is currently trading at $34.14. The RSI (14-day) is at 66.1, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $51.07 implies 49.6% upside from current levels. Volatility is high at 76.0% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Beam Therapeutics Inc. (BEAM): The trailing P/E ratio is -69.67, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -6.28. Price-to-Book is 2.91. Price-to-Sales is 21.41. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 15 analysts covering BEAM, the consensus price target is $51.07. This represents a 49.6% upside from the current price of $34.14. The range spans from a low target of $26.00 to a high target of $80.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Beam Therapeutics Inc. (BEAM) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Beam Therapeutics Inc. (BEAM) investors include: 1. High volatility (76.0% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (39.9% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Beam Therapeutics Inc.'s (BEAM) current debt and financial health profile: Total debt stands at $250.82M. The debt-to-equity ratio is 21.54, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 16.99, indicating strong short-term liquidity. The quick ratio is 16.25. The company holds $1.21B in cash and equivalents. Free cash flow is negative at $-233,555,744, which could limit the company's ability to manage debt obligations.